Zacks Investment Research Upgrades Opexa Therapeutics Inc (OPXA) to “Hold”
Opexa Therapeutics Inc (NASDAQ:OPXA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday, May 24th.
According to Zacks, “Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company’s lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes. “
Opexa Therapeutics (NASDAQ OPXA) traded up 1.2521% during mid-day trading on Wednesday, reaching $0.5984. 7,697 shares of the company traded hands. Opexa Therapeutics has a 12-month low of $0.50 and a 12-month high of $4.93. The company’s 50 day moving average price is $0.61 and its 200 day moving average price is $0.83. The firm’s market capitalization is $4.58 million.
Opexa Therapeutics (NASDAQ:OPXA) last announced its quarterly earnings data on Friday, May 12th. The biopharmaceutical company reported ($0.12) EPS for the quarter. Equities research analysts predict that Opexa Therapeutics will post ($0.47) EPS for the current year.
About Opexa Therapeutics
Opexa Therapeutics, Inc (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Opexa Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc and related stocks with our FREE daily email newsletter.